Prix Galien USA 2021

Nominees for Best Pharma

The onset of COVID-19 has upended the business of health care, including the $1 trillion global market for prescription pharmaceuticals. Reliance on the R&D industry to develop a vaccine to defeat the contagion has introduced new obligations and raised the stakes on drug makers reputation and responsibility to society.

On the positive side, it has created new incentives for collaborative partnerships, particularly with regulators. The down side is the slower pace of new market launches in other areas of unmet patient need, a decline in elective procedures requiring drugs, and more distractions among providers, payers and key institutional clients who remain focused on managing their own pandemic-related exposures. The fact is there is no real consensus on how the pandemic will reshape the future of health provision, financing, government regulation and patient expectations. Learnings from the pandemic crisis may lead to new entrants to the medicines market as well as a greater role for public intervention in regulating the distribution and cost of care. Those who can leverage productivity gains from advanced information technologies like AI and digital medicine, including many from outside health care itself, have the potential to disrupt big pharma’s pre-pandemic business model for good. To mark the Prix Galien USA’s upcoming October 27 “Week of Discovery and Celebration on the Frontiers of Medical Innovation,” distinguished members of the USA Galien Awards Committee will chair six webinars highlighting each of the 34 nominee products they have selected in the best Pharmaceuticals category.

These virtual expert panelist exchanges will offer the opportunity for webinar participants to review the current state of innovation in biopharma, covering key aspects of clinical progress and differentiation; the ways that patient care is now being conducted outside the traditional delivery setting; and the next wave of promising digital and gene-based drug therapies, including their transformative – and potentially disruptive – effect on health care productivity and outcomes worldwide.

Best Pharmaceutical Product Nominees 2021

ProductCompanyTherapeutic Area &
Indication
Adakveo® (crizanlizumab-tmca)Novartis Pharmaceuticals CorporationTreatment to lower frequency of recurrent vaso- occlusive crises associated with severe vascular system pain for conditions like sickle cell anemia
Read more
Adhansia XR®Adlon Therapeutics L.P.,
a subsidiary of Purdue Pharma L.P.
Central nervous system stimulant to treat attention deficit hyperactivity disorder (ADHD)
in people age six and older
Read more
AnnoveraTMPopulation Council and TherapeuticsMDNovel hormonal contraceptive vaginal ring that prevents ovulation and pregnancy over a full-year cycle of use
Read more
ASPARLAS®Servier PharmaceuticalsComponent therapy of a multi-agent chemotherapy regimen for treatment of acute lymphoblastic leukemia (ALL) in patients 21 years of age or younger
Read more
Entresto® (sacubitril/valsartan)Novartis Pharmaceuticals CorporationReduce hospitalizations and deaths in adults with chronic heart failure through improvement
in the heart’s ability to pump blood to the body
Read more
Gamifant®SobiFirst treatment for infants/adults with primary haemophagocytic lymphohistiocytosis (HLH), an ultra-rare immune disorder that leads to severe inflammation, infections, bleeding, organ failures and early death
Read more
LORBRENA®Pfizer Inc.For patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) in cases where previous ALK inhibitors have failed
Read more
Lutathera®Advanced Accelerator ApplicationsRadioactive isotope treatment for cancerous neuroendocrine tumors affecting the pancreas or gastrointestinal tract
Read more
MoxidectinMedicines Development for Global Health & TDRNew treatment for onchocerciasis (river blindness) demonstrating superiority over ivermectin, the current standard of care against this major neglected infectious disease prevalent
in developing countries
Read more
Nubeqa®BayerFor patients with non-metastatic castration-resistant prostate cancer
Read more
Olumiant®Eli Lilly and CompanyJAK inhibitor for treatment of Rheumatoid Arthritis in patients who fail to benefit from existing TNF alpha inhibitor therapies
Read more
Piqray® (alpelisib)Novartis Pharmaceuticals CorporationTreatment of advanced or metastatic breast cancer with PIK3CA gene mutation
Read more
RECARBRIOTMMerck & Co., Inc.Combination anti-bacterial for adults with complicated urinary tract infections and complicated intra-abdominal infections
Read more
REYVOW®Eli Lilly and CompanyA serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with
or without aura in adults
Read more
RINVOQTMAbbVieJAK (janus kinase) inhibitor that blocks inflammation of moderate to severe rheumatoid arthritis (RA)
in patients who don’t benefit from existing treatments
Read more
RozlytrekTMGenentech, Inc.First “tumor agnostic” treatment with biomarkers
to specifically target ROS-1 positive metastatic non-small cell lung cancer (NSCLC) as well as other NTRK gene fusion positive solid tumors
Read more
TPOXX®SIGA Technologies, Inc.First drug with an indication for treatment
of smallpox in humans in the event of its use as a bioweapon and public health emergency
Read more
VITRAKVI®BayerRead more
XPOVIO®Karyopharm Therapeutics Inc.Treatment of relapsed/refractory (RR) multiple myeloma and RR diffuse large B-cell lymphoma
Read more
XOSPATA®Astellas Pharma Inc.Tyrosine kinase inhibitor for adults with relapsed or refractory acute myeloid leukemia (AML) with the tyrosine kinase-3 gene mutation
Read more
Nurtec® ODTBiohaven PharmaceuticalsAcute treatment of migraine
Read more
AYVAKITTM (avapritinib)Blueprint MedicinesTreatment of gastrointestinal stromal tumor
Read more
GAVRETO® (pralsetinib)Blueprint MedicinesTreatment of lung cancer
Read more
QINLOCK®Deciphera PharmaceuticalsTreatment of gastrointestinal stromal tumor
Read more
ELYXYBDr. Reddy’s Laboratories LtdTreatment of migraine
Read more
ZOKINVY®Eiger BioPharmaceuticals, Inc.Treatment of genetic diseases of premature aging in children and young adults
Read more
TAZVERIK®Epizyme Inc.Treatment of sarcoma or refractory follicular lymphoma
Read more
NEXLETOLEsperion Therapeutics Inc.Treatment of hypercholesterolemia
Read more
NEXLIZETEsperion Therapeutics Inc.Treatment of hypercholesterolemia
Read more
Veklury®Gilead Sciences, Inc.For the treatment of coronavirus disease 2019 (COVID-19)
Read more
Pemazyre® (pemigatinib)IncyteTreatment of cholangiocarcinoma
Read more
ORGOVYX® (Relugolix)Myovant Sciences, Inc.Treatment of advanced prostate cancer
Read more
Braftovi® Mektovi®Pfizer Inc.Treatment of metastatic melanoma
Read more
TUKYSASeagenTreatment of breast cancer
Read more